Skip to main content

Table 4 Multivariate analyses of prognostic factors for disease-specific survival of patients with early or advanced stage tumors in the study cohort

From: Upregulation of NETO2 expression correlates with tumor progression and poor prognosis in colorectal carcinoma

Variables

Categories

Early stage

Advanced stage

  

HR

95 % CI

P valueb

HR

95 % CI

P valueb

Age (years)

≥60/<60

1.705

0.860-3.381

0.127

2.229

1.264-3.932

0.006

Sex

Male/female

0.818

0.462-1.447

0.489

1.575

0.934-2.658

0.089

Tumor location

Colon/rectum

1.095

0.802-1.495

0.569

0.968

0.727-1.290

0.826

Tumor size (cm)

≥5/<5

0.920

0.536-1.579

0.762

1.558

0.915-2.652

0.103

No. of examined lymph nodes

≥12/< 12

1.525

0.785-2.964

0.213

0.584

0.351-0.973

0.039

Bowel obstruction/perforation

Yes/no

1.365

0.175-10.672

0.767

0.689

0.209-2.269

0.541

Adjuvant chemotherapya

Yes/no

0.808

0.397-1.644

0.556

   

Differentiation grade

Poor/well + moderate

0.690

0.207-2.298

0.545

1.591

0.946-2.678

0.080

NETO2 expression

High/low

1.937

1.107-3.390

0.021

2.241

1.245-4.035

0.007

  1. Abbreviations: HR, hazard ratio; 95 % CI, 95 % confidence interval
  2. aAs all advanced stage patients had received adjuvant chemotherapy, adjuvant chemotherapy was not enrolled into the multivariate analysis
  3. bBold type indicates statistical significance